NCT07119606: EUQ13

Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)

Not yet recruiting NA Last updated 13 August 2025

What this trial tests

NA trial testing SHANK3 mutation in Genetic Disease in 650 participants. Not yet recruiting.

Timeline

1 September 2025

Primary endpoint
1 March 2027

1 March 2027

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	650
Start date	1 September 2025
Primary completion	1 March 2027
Estimated completion	1 March 2027
Sites	1 location across France

Drugs / interventions tested

• SHANK3 mutation

Conditions studied

• Genetic Disease — all drugs for Genetic Disease →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 3 Months to 99, any sex, with Genetic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder with extensive clinical and genetic heterogeneity that is still poorly understood. The phenotype includes hypotonia, delayed psychomotor development, intellectual disability of varying severity, and consistent language impairment ranging from delayed to absent speech. Autism spectrum disorders are present in 60-80% of patients, and other comorbidities may be present. The major candidate gene for PMS is SHANK3, which encodes a scaffolding protein in the dense postsynaptic region of glutamatergic synapses. Its loss of function is caused by deletions in the distal region of chromosome 22, 22q13.3, or by intragenic genomic variants. Several studies, including the one conducted by our team, have shown that part of the variability in the phenotype is related to the size of the 22q13.3 deletion. However, two patients with a deletion of similar size or an identical point variation in SHANK3 can have phenotypes of very variable severity.

The existence of additional genomic variants not identified by standard diagnostic techniques, particularly DNA chip chromosomal analysis (ACPA), which may act as modulating elements of the phenotype, has been suggested.

The limitations of the proposed studies are the highly heterogeneous genomic tools used (variable DNA chip design in terms of probe distribution and resolution) and the often imprecise phenotypes. Our study will bring together a large number of SPM patients (related to a 22q13.3 deletion or a variation of the SHANK3 gene) as well as their parents and possible relatives (first or second degree of the patient), very well phenotyped and explored by complete genome sequencing on the same sequencing platform.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.